Free tool
FAERS Monitor: Zirabev
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761099 or its brand name (Zirabev, Bevacizumab-Bvzr). Reports on generic versions are filed under their own applications.
Reports
705
Serious
568
81% of reports
Hospitalization
166
Death reported
207
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use171
- death162
- neoplasm progression82
- fatigue68
- weight decreased47
- hypertension46
- blood pressure increased44
- weight increased37
- inappropriate schedule of product administration32
- malaise32
- asthenia30
- nausea30
- dyspnoea27
- blood pressure fluctuation26
- blood pressure systolic increased26
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 39 |
| 2021 | 91 |
| 2022 | 159 |
| 2023 | 164 |
| 2024 | 148 |
| 2025 | 66 |
| 2026 | 38 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,454 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| neoplasm progressionSignal | 82 | 70.5 | 57.5 | 5,548 |
| blood pressure systolic increasedSignal | 26 | 39.8 | 27.3 | 945 |
| blood pressure fluctuationSignal | 26 | 32.4 | 22.2 | 759 |
| blood pressure increasedSignal | 44 | 8.6 | 6.5 | 289 |
| hypertensionSignal | 46 | 6.5 | 4.9 | 210 |
| off label useSignal | 171 | 5.8 | 5.1 | 708 |
| deathSignal | 162 | 5.6 | 4.9 | 635 |
| inappropriate schedule of product administrationSignal | 32 | 5.3 | 3.8 | 108 |
| weight decreasedSignal | 47 | 5.0 | 3.8 | 149 |
| weight increasedSignal | 37 | 4.9 | 3.6 | 113 |
| fatigueSignal | 68 | 2.6 | 2.1 | 68 |
| astheniaSignal | 30 | 2.4 | 1.7 | 23 |
| malaiseSignal | 32 | 2.2 | 1.6 | 20 |
| dyspnoea | 27 | 1.4 | 1.0 | 3 |
| nausea | 30 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.